Cargando…

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer

Anti-PD-1/PD-L1 antibodies have been proved one of the most promising treatments against non-small cell lung cancer (NSCLC); however, whether anti-PD-1/PD-L1 antibodies can provide added benefits for pretreated patients with advanced NSCLC and which patients are most likely to benefit from anti-PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Qi, Xie, Mixue, He, Mengye, Yan, Feifei, Zhang, Xiaochen, Yu, Sufen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800935/ https://www.ncbi.nlm.nih.gov/pubmed/29484143 http://dx.doi.org/10.18632/oncotarget.23584

Ejemplares similares

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018)

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ang, et al.
Publicado: (2017)

Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis
por: Geng, Zhe, et al.
Publicado: (2018)

Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
por: Qian, Da, et al.
Publicado: (2023)

Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials
por: Man, Johnathan, et al.
Publicado: (2021)

Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects
por: Zhang, Wenjing, et al.
Publicado: (2021)

Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Polintan, Edgar Theodore, et al.
Publicado: (2022)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
por: Wenfan, Fu, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
por: Lan, Bo, et al.
Publicado: (2018)

Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis
por: Zhang, Qian, et al.
Publicado: (2020)

Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis
por: Guo, Wei, et al.
Publicado: (2017)

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study
por: Jin, Liu, et al.
Publicado: (2020)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
por: Li, Yan, et al.
Publicado: (2023)

Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
por: Ramos-Esquivel, Allan, et al.
Publicado: (2017)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
por: Chen, Jianxin, et al.
Publicado: (2019)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients
por: Wu, Bing, et al.
Publicado: (2023)

Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials
por: Teutsch, Brigitta, et al.
Publicado: (2021)

Comparison of Surgical Techniques in Living Donor Nephrectomy: A Systematic Review and Bayesian Network Meta-Analysis
por: Xiao, Qi, et al.
Publicado: (2020)

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
por: Li, Bo, et al.
Publicado: (2019)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Laparoscopic versus Open Resection of Small Bowel Gastrointestinal Stromal Tumors: Systematic Review and Meta-analysis
por: Chen, Ke, et al.
Publicado: (2017)

Safety and efficiency of flow diverters for treating small intracranial aneurysms: A systematic review and meta-analysis
por: Yao, Xiyang, et al.
Publicado: (2017)

MTHFR C677T Polymorphism is Associated with Tumor Response to Preoperative Chemoradiotherapy: A Result Based on Previous Reports
por: Zhao, Yue, et al.
Publicado: (2015)

Diagnostic value of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in rheumatoid arthritis in Asia: a meta-analysis
por: Yang, Xiaochun, et al.
Publicado: (2021)

Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Nijiao, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020)

Pulmonary function after segmentectomy versus lobectomy in patients with early-stage non-small-cell lung cancer: a meta-analysis
por: Wang, Xinxin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jss2n231l2510fqub3a7rdmtgp